Shares of Vertex Energy, Inc. (VTNR) plummeted more than 58% on Wednesday after the producer and marketer of refined products announced a Restructuring Support Agreement (RSA) with lenders andfiled for bankruptcy protection. With full support from its lenders, Vertex Energy has commenced a Chapter 11 case in the United States Bankruptcy Court for the Southern District of Texas to expedite the transactions under the RSA. The decision comes after the company failed in the renewable energy sector. Vertex's Res ...

Daniel Grizelj I believe that Vertex (NASDAQ:VRTX) stock is significantly undervalued because investors are massively underestimating the value of the company's pain treatment, VX-548. In my view, there's a good chance of VX-548 becoming a huge blockbuster. That's because I think there's a great hunger in America for a drug which treats pain more effectively than acetaminophen and NSAIDs and which patients are unlikely to abuse. And according to my calculations, Vertex's shares do not come close to reflecti ...

The stock of Vertex Pharmaceuticals Incorporated (VRTX) has declined around 1.2% in the past three months, losing almost $3 billion of its market value. A key reason for the stock price dip was the loss recorded by the company in the second quarter due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences, which closed in May. Vertex enjoys a dominant position in the cystic franchise ("CF") market. Vertex's CF sales continue to grow, driven by its triple therapy, Trikafta/Kaftrio. Verte ...

KING OF PRUSSIA, Pa., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a global provider of tax technology solutions, today announced that David DeStefano, Chief Executive Officer, and John Schwab, Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia + Technology Conference on Monday, September 9, 2024 at 9:30 AM Pacific Time. Live webcasts and replays of both presentations will be available on Vertex's investor relations website at ir.vertex.com. Abou ...

Klaus Vedfelt Investment Overview Vertex Pharmaceuticals (NASDAQ:VRTX), the Boston based Pharma giant with an almost monopolistic share of the Cystic Fibrosis treatment market, announced its Q2 2024 earnings at the beginning of August. Product revenues were $2.65bn - up 6% year-on-year. GAAP R&D and SG&A expenses were $1.3bn, and operating income was reported as $934.9m, resulting in an operating margin of ~35%. Thanks to Vertex' completion of its $4.4bn buyout of Alpine Immune Sciences, the kidney disease ...

KING OF PRUSSIA, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ: VERX) ("Vertex" or the "Company"), a leading global provider of indirect tax solutions, today announced that it has completed the acquisition of ecosio, a leading B2B integration provider specializing in electronic data interchange (EDI) and e-invoicing, as of August 30, 2024. David DeStefano, CEO of Vertex, stated, "We welcome the ecosio team to the Vertex family. E-invoicing is going to change the way international companies han ...

Investors might want to bet on Vertex (VERX) , as earnings estimates for this company have been showing solid improvement lately. The stock has already gained solid short-term price momentum, and this trend might continue with its still improving earnings outlook. The rising trend in estimate revisions, which is a result of growing analyst optimism on the earnings prospects of this company, should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in ea ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock. By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks bey ...

Images By Tang Ming Tung Investment summary My previous investment thought for Vertex, Inc. (NASDAQ:VERX) (published in June) was a buy rating because of the attractive growth outlook, supported by strong secular tailwinds and growth catalysts. I remain bullish about the potential upside, as VERX is not seeing any signs of growth slowdown. On the flip side, I have become more confident that VERX can continue to capitalize on the ECC to S/4HANA migration trend. The new acquisition is also a positive one that ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. But finding a great growth stock is not easy at all. By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss. However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks bey ...